search for


Medical Specialists’ Perceptions and Attitudes Towards Biosimilar Prescription
Yakhak Hoeji 2020;64(6):438-445
Published online December 31, 2020
© 2020 The Pharmaceutical Society of Korea.

Eunsol Song and Sylvia Park#

Korea Institute for Health and Social Affairs
Correspondence to: Sylvia Park, Korea Institute for Health and Social Affairs, 370 Sicheong-daero, Sejong City 30147, Korea
Tel: +82-44-287-8134, Fax: +82-44-287-8063
Received August 31, 2020; Revised October 20, 2020; Accepted December 12, 2020.
Biosimilars are a cost-effective alternative to their originator biologics with the potential to increase access to biological medicine and provide savings to the health care system. Currently, in Korea, there are few data on physicians’ perceptions of biosimilars and reasons for either prescribing biosimilars or not. This study investigated the current levels of prescribing experiences, perceptions, and willingness to prescribe biosimilars among specialist physicians in Korea. An online survey was conducted from July 30 to August 10, 2018. Responses were obtained from 200 healthcare professionals across the specialties of rheumatology, dermatology, gastroenterology, medical oncology, and surgical oncology. Most respondents (91.5%) had experience prescribing original biologics and 56.5% had experience in prescribing biosimilars. The main reasons for prescribing biosimilars were cost advantages and confidence in the efficacy and safety of biosimilars. Respondents showed positive views on biosimilars, with 71.5 and 83% confidence in interchangeability, efficacy, and safety of biosimilars, but less confidence in switching from an originator biologic to a biosimilar. Based on the results of this study, a strategy for promoting biosimilar market entry could be prepared to enhance social benefits.
Keywords : biosimilar, physician, perception, attitude

December 2020, 64 (6)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)

Funding Information